In a study on lung adenocarcinoma, four fusion genes (WISP1, RAMP1, MYBL2, and GATA2) of the human leukocyte antigen (HLA) family were identified by RNA-seq technology, indicating that the HLA family genes might be potential targets for the lung adenocarcinoma therapy. This evidence concerns the gene RAMP1 and lung adenocarcinoma.